when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

GLP-1 receptor · news · pharmadog

← back to GLP-1 receptor

News · GLP-1 receptor

341 stories

27dStructure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data dropbiospace

27dMoonwalk pulls in $70M to take fat-targeting RNAi obesity candidate to clinicbiospace

27dAn administrative gap delays access to new pancreatic cancer treatmentstat

27dOpinion: I’m a fat medical student. I refuse to let myself be shamed for itstat

Sep 4, 26This week in charts: China deals, stock flatlines and Lilly’s M&A spreebiopharma dive

Sep 4, 26Italy's Menarini gets into obesity with European rights to GLP-1 from China's Gan & Leeendpoints

Sep 4, 26Menarini signs $771M deal to take Gan & Lee GLP-1 to European marketfiercebiotech

Sep 3, 26An AI drug specialist zeroes in on rare forms of obesitybiopharma dive

Sep 2, 26Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical modelsbiospace

Sep 2, 26Opinion: The next DSM should address the algorithm’s role in eating disordersstat

Sep 1, 26From his parents’ basement to your medicine cabinet: Absci CEO endeavors to create biotech’s Applefiercebiotech

Aug 31, 26New guidelines on migraine prevention reflect increasing options for patientsstat

Aug 31, 26STAT+: Can buying a drug patent application be seen as a bid to prolong a monopoly?stat

Aug 31, 26STAT+: GLP-1 drugs are almost single-handedly forcing employers to reconsider workers’ health carestat

Aug 31, 26STAT+: We’re reading about drug pricing deals, a new cancer therapy approval, and morestat

Aug 31, 26Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodiesfiercebiotech

Aug 28, 26STAT+: Up and down the ladder: The latest comings and goingsstat

Aug 28, 26Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist Mounjarobiospace

Aug 28, 26STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and morestat

Aug 28, 26Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical datafiercebiotech

Aug 27, 26Impacts of CMS’ GLP-1 pilot program begin to take shapeendpoints

Aug 27, 26Lilly's move to hide Phase 1 pipeline draws mixed reviewsendpoints

Aug 27, 26STAT+: Pharmalittle: We’re reading about a pancreatic cancer drug approval, a Trump deal with biotechs, and morestat

Aug 27, 26Myriad catalysts on deck for obesity’s brightest stars as market continues to acceleratebiospace

Aug 26, 26On the fence about a statin? In borderline cases, calcium scans could be a tiebreakerstat

Aug 26, 26STAT+: Pharmalittle: We’re reading about a GSK shingles shot, U.S. employers dropping GLP-1 coverage, and morestat

Aug 26, 26Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealedbiospace

Aug 24, 26Roche commits to lean-mass preservation with Hanmi obesity dealbiopharma dive

Aug 24, 26STAT+: Pharmalittle: We’re reading about Medicaid obesity-drug coverage, a Regenxbio gene therapy, and morestat

Aug 24, 26Roche bets up to $2.3B in Hanmi pact for next-gen weight loss drugbiospace

← prevpage 4 of 12next →